Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs MVT 1075 (Primary) ; MVT 5873 (Primary)
- Indications Colon cancer; Lung cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors MabVax Therapeutics
- 16 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 16 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 15 Mar 2018 According to a MabVax Therapeutics media release, interim results of the study will be present at the 2018 American Association for Cancer Research (AACR) Annual Meeting